Complex cardiac defect with hypoplastic right ventricle in a fetus with valproate exposure

Prenatal Diagnosis

Volumn 25, Issue 2, 2005, Pages 156-158

  Ten Berg, K ^a   Van Oppen, A C C ^a   Nikkels, P G J ^a   Gittenberger De Groot, A C ^b   Van Der Voet, G B ^b   Brilstra, E H ^a   Lindhout, D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiac malformation; Heart defect; Hypoplastic right ventricle; Valproate; Valproic acid

Indexed keywords

ALPHA FETOPROTEIN; FOLIC ACID; VALPROIC ACID;

ADULT; AMNION FLUID CYTOLOGY; ARTICLE; AUTOPSY; CASE REPORT; CONGENITAL HEART MALFORMATION; FEMALE; FETUS; FETUS ECHOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; GENERALIZED EPILEPSY; HUMAN; HUMAN TISSUE; HYPOPLASTIC RIGHT VENTRICLE; MALE; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

ABORTION, INDUCED; ADULT; ANTICONVULSANTS; DIAGNOSIS, DIFFERENTIAL; EPILEPSY; FEMALE; HEART DEFECTS, CONGENITAL; HEART VENTRICLES; HUMANS; MIGRAINE DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, SECOND; ULTRASONOGRAPHY, PRENATAL; VALPROIC ACID;

EID: 14744271533     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1098     Document Type: Article

References (12)

1. Binkerd PE, Rowland JM, Nau H, Hendrickx AG. 1988. Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam Appl Toxicol 11: 485-493.
2. Craig J, Morrison P, Morrow J, Patterson V. 1999. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 8: 253-254.
3. Dalens B, Raynaud EJ, Gaulme J. 1980. Teratogenicity of valproic acid. J Pediatr 97: 332-333.
4. Hendrickx AG, Nau H, Binkerd P, et al. 1988. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Teratology 38: 329-345.
5. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. 2000. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 343: 1608-1614.
6. Kozma C. 2001. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 98: 168-175.
7. Menegola E, Broccia ML, Nau H, Prati M, Ricolfi R, Giavini E. 1996. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen 16: 97-108.
8. Padmanabhan R, Shafiullah MM. 2003. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto) 43: 29-40.
9. Samrén EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. 1999. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46: 739-746.
10. Sonoda T, Ohdo S, Ohba K, Okishima T, Hayakawa K. 1993. Sodium valproate-induced cardiovascular abnormalities in the Jcl: ICR mouse fetus: peak sensitivity of gestational day and dose-dependent effect. Teratology 48: 127-132.
11. Thisted E, Ebbesen F. 1993. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 69: 288-291.
12. Trotz M, Wegner C, Nau H. 1987. Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse. Life Sci 41: 103-110.